Swiss National Bank increased its position in shares of Intellia Therapeutics Inc (NASDAQ:NTLA) by 91.8% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 39,700 shares of the company’s stock after acquiring an additional 19,000 shares during the period. Swiss National Bank owned about 0.11% of Intellia Therapeutics worth $763,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Nationwide Fund Advisors raised its stake in Intellia Therapeutics by 117.7% during the 2nd quarter. Nationwide Fund Advisors now owns 8,048 shares of the company’s stock worth $129,000 after buying an additional 4,351 shares during the period. New York State Common Retirement Fund increased its holdings in Intellia Therapeutics by 109.7% during the 2nd quarter. New York State Common Retirement Fund now owns 15,100 shares of the company’s stock worth $242,000 after purchasing an additional 7,899 shares in the last quarter. Vanguard Group Inc. increased its holdings in Intellia Therapeutics by 10.2% during the 2nd quarter. Vanguard Group Inc. now owns 997,288 shares of the company’s stock worth $15,957,000 after purchasing an additional 92,580 shares in the last quarter. Ark Investment Management LLC increased its holdings in Intellia Therapeutics by 118.9% during the 2nd quarter. Ark Investment Management LLC now owns 174,810 shares of the company’s stock worth $2,797,000 after purchasing an additional 94,960 shares in the last quarter. Finally, Dimensional Fund Advisors LP bought a new stake in Intellia Therapeutics during the 2nd quarter worth approximately $695,000. Hedge funds and other institutional investors own 57.10% of the company’s stock.
In other news, major shareholder Caribou Biosciences, Inc. sold 550,645 shares of Intellia Therapeutics stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $26.78, for a total transaction of $14,746,273.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jean Francois Formela sold 39,245 shares of Intellia Therapeutics stock in a transaction that occurred on Tuesday, March 20th. The shares were sold at an average price of $23.87, for a total transaction of $936,778.15. The disclosure for this sale can be found here. 12.80% of the stock is owned by company insiders.
A number of brokerages have commented on NTLA. TheStreet raised Intellia Therapeutics from a “d” rating to a “c-” rating in a report on Monday, March 19th. BidaskClub lowered Intellia Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Wednesday, March 21st. Leerink Swann reissued an “outperform” rating on shares of Intellia Therapeutics in a report on Wednesday, March 14th. Wedbush restated an “outperform” rating and set a $36.00 target price on shares of Intellia Therapeutics in a research report on Thursday, March 15th. Finally, JMP Securities initiated coverage on Intellia Therapeutics in a research report on Thursday, March 8th. They set an “outperform” rating on the stock. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have issued a buy rating to the stock. Intellia Therapeutics has an average rating of “Buy” and a consensus target price of $34.83.
Shares of NASDAQ:NTLA traded down $1.41 on Friday, reaching $20.45. 1,121,251 shares of the company traded hands, compared to its average volume of 1,603,846. Intellia Therapeutics Inc has a 52 week low of $11.15 and a 52 week high of $35.99. The stock has a market capitalization of $926.59, a P/E ratio of -10.88 and a beta of 2.83.
Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings data on Wednesday, March 14th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.45) by ($0.16). The company had revenue of $6.70 million for the quarter, compared to the consensus estimate of $8.84 million. Intellia Therapeutics had a negative net margin of 258.62% and a negative return on equity of 31.27%. The firm’s quarterly revenue was up 19.6% compared to the same quarter last year. During the same period last year, the business posted ($0.31) earnings per share. research analysts expect that Intellia Therapeutics Inc will post -2.27 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Intellia Therapeutics Inc (NTLA) Shares Bought by Swiss National Bank” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/04/07/swiss-national-bank-raises-position-in-intellia-therapeutics-inc-ntla.html.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.